Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Revenue (2021)

Atea Pharmaceuticals' Revenue history spans 1 years, with the latest figure at $192.2 million for Q4 2021.

  • Quarterly Revenue changed N/A to $192.2 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $351.4 million through Dec 2021, changed N/A year-over-year, with the annual reading at $351.4 million for FY2021, 622.49% up from the prior year.
  • Revenue came in at $192.2 million for Q4 2021, up from $32.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $192.2 million in Q4 2021 to a low of $32.8 million in Q3 2021.